MCID: SML016
MIFTS: 50

Small Intestine Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Small Intestine Cancer

MalaCards integrated aliases for Small Intestine Cancer:

Name: Small Intestine Cancer 12 52 15
Small Intestine Carcinoma 12 15 17 71
Malignant Neoplasms of the Small Intestine 52
Malignant Tumor of Small Intestine 71
Neoplasm of Small Intestine 71
Small Intestinal Carcinoma 12
Cancer of the Small Bowel 12
Small Bowel Cancer 12
Small Bowel Tumors 52

Classifications:



External Ids:

Disease Ontology 12 DOID:10154 DOID:4907
ICD9CM 34 152.9
NCIt 49 C7523 C7724
SNOMED-CT 67 94048009
ICD10 32 C17 C17.9
UMLS 71 C0153425 C0238196 C0345832

Summaries for Small Intestine Cancer

Disease Ontology : 12 A small intestine cancer that develops from epithelial cells and is located in the small intestine.

MalaCards based summary : Small Intestine Cancer, also known as small intestine carcinoma, is related to small intestine adenocarcinoma and gallbladder cancer. An important gene associated with Small Intestine Cancer is MSH6 (MutS Homolog 6), and among its related pathways/superpathways are TCR Signaling (Qiagen) and Gastric cancer. The drugs Prucalopride and Gastrointestinal Agents have been mentioned in the context of this disorder. Affiliated tissues include small intestine, colon and thyroid, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Small intestine cancer is a cancer of the small intestine. It is relatively rare compared to other... more...

Related Diseases for Small Intestine Cancer

Diseases in the Small Intestine Cancer family:

Large Intestine Cancer Intestine Carcinoma in Situ
Rare Carcinoma of Small Intestine

Diseases related to Small Intestine Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 437)
# Related Disease Score Top Affiliating Genes
1 small intestine adenocarcinoma 32.4 SMAD4 PMS2 MUC6 MSH6 MSH2 MLH1
2 gallbladder cancer 30.9 TP53 SMAD4 MUC1 MLH1 KRT7 KRAS
3 intestinal obstruction 30.6 KRT7 CEACAM5 CDX2
4 neuroendocrine tumor 30.5 MEN1 HRAS GAST CDX2
5 descending colon cancer 30.4 KRAS CEACAM5 CDX2
6 familial colorectal cancer 30.3 TP53 MUTYH MSH2 MLH1
7 pancreatitis 30.2 TP53 SMAD4 KRAS HRAS
8 desmoid tumor 30.2 MUTYH CTNNB1 AFAP1
9 gastritis 30.2 TP53 MUC6 GAST CDX2
10 neurofibromatosis, type iv, of riccardi 30.1 TP53 MEN1 KRAS HRAS
11 mismatch repair cancer syndrome 30.1 PMS2 MSH6 MSH2 MLH1 CTNNB1
12 jejunal cancer 30.1 PMS2 MUTYH MSH6 MSH2 MLH1 KRT7
13 peutz-jeghers syndrome 30.1 TP53 SMAD4 MUC6 CTNNB1
14 angiosarcoma 30.0 TP53 MUC1 KRT7 KRAS
15 jejunal adenocarcinoma 30.0 MSH6 MLH1 KRT7 CEACAM5 CDX2
16 colonic disease 30.0 TP53 MLH1 KRAS HRAS CEACAM5
17 appendix adenocarcinoma 30.0 KRT7 KRAS HRAS CEACAM5 CDX2
18 biliary tract disease 29.9 TP53 KRT7 KRAS HRAS CEACAM5
19 peptic ulcer disease 29.9 TP53 MUC5AC MEN1 HRAS GAST
20 benign mesothelioma 29.9 KRT7 CEACAM5
21 papillary adenocarcinoma 29.8 TP53 MUC1 KRT7 KRAS CEACAM5
22 hemangioma 29.7 TP53 MUC1 MEN1 KRT7 KRAS
23 rectum cancer 29.7 MUTYH MSH6 MSH2 MLH1 KRAS HRAS
24 glioblastoma multiforme 29.6 TP53 PMS2 MSH2 MLH1 KRAS HRAS
25 sarcoma 29.6 TP53 MUC1 MSH2 KRAS HRAS CTNNB1
26 small cell carcinoma 29.6 TP53 MUC1 KRT7 KRAS GAST CDX2
27 neuroendocrine carcinoma 29.6 MUC1 MEN1 KRT7 GAST CEACAM5
28 gastrointestinal carcinoma 29.5 TP53 MUC1 GAST EPCAM CEACAM5 CDX2
29 tubular adenocarcinoma 29.4 MUC5AC MUC1 KRT7 CTNNB1 CEACAM5 CDX2
30 duodenum adenocarcinoma 29.4 PMS2 MUC6 MUC5AC MSH6 MSH2 MLH1
31 familial adenomatous polyposis 29.4 TP53 SMAD4 MUTYH MSH6 MSH2 MLH1
32 duodenum cancer 29.2 SMAD4 PMS2 MUTYH MUC6 MUC5AC MUC1
33 mucinous adenocarcinoma 29.2 TP53 MUC5AC MUC1 MLH1 KRT7 KRAS
34 lynch syndrome 29.2 TP53 SMAD4 PMS2 MUTYH MSH6 MSH2
35 colon adenocarcinoma 29.1 TP53 SMAD4 PMS2 MSH6 MLH1 KRAS
36 esophageal cancer 28.7 TP53 SMAD4 MUC1 MSH2 MLH1 KRAS
37 signet ring cell adenocarcinoma 28.6 TP53 MUC6 MUC5AC MUC1 MSH2 MLH1
38 pseudomyxoma peritonei 28.5 TP53 MUC6 MUC5AC MUC1 KRT7 KRAS
39 colorectal adenocarcinoma 28.5 TP53 PMS2 MUC1 MSH6 MSH2 MLH1
40 adenocarcinoma 28.4 TP53 SMAD4 MUC1 MSH6 MSH2 MLH1
41 endometrial cancer 28.2 TP53 SMAD4 PMS2 MUTYH MUC1 MSH6
42 gastric adenocarcinoma 28.2 TP53 SMAD4 MUC1 MLH1 KRT7 KRAS
43 adenoma 27.9 TP53 SMAD4 MUTYH MUC6 MUC5AC MUC1
44 gastric cancer 27.8 TP53 SMAD4 MUTYH MUC6 MUC5AC MUC1
45 colorectal cancer 27.0 TP53 SMAD4 PMS2 MUTYH MUC6 MUC5AC
46 small intestine carcinoid neuroendocrine tumor 11.1
47 ileum cancer 11.1
48 spindle cell intraocular melanoma 10.7 PMS2 MLH1
49 trachea carcinoma in situ 10.6 KRAS HRAS
50 actinic cheilitis 10.6 TP53 MSH2

Comorbidity relations with Small Intestine Cancer via Phenotypic Disease Network (PDN):


Colorectal Cancer Deficiency Anemia
Intestinal Obstruction

Graphical network of the top 20 diseases related to Small Intestine Cancer:



Diseases related to Small Intestine Cancer

Symptoms & Phenotypes for Small Intestine Cancer

GenomeRNAi Phenotypes related to Small Intestine Cancer according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.3 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.3 CTNNB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.3 MLH1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.3 KRT7
5 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.3 MLH1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.3 CTNNB1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.3 CTNNB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.3 KRT7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.3 CTNNB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.3 MLH1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.3 SMAD4
12 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.3 SMAD4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.3 SMAD4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.3 SMAD4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.3 SMAD4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.3 CTNNB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.3 CTNNB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.3 SMAD4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.3 CTNNB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.3 CTNNB1 SMAD4
21 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.3 CTNNB1 KRT7 MLH1 SMAD4
22 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.3 MLH1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.3 SMAD4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.3 MLH1
25 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.56 AFAP1 MEN1 MLH1 MSH2 MSH6 MUTYH
26 Reduced mammosphere formation GR00396-S 9.17 HRAS KRAS KRT7 MEN1 MUC5AC MUTYH

MGI Mouse Phenotypes related to Small Intestine Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.25 CDX2 CTNNB1 EPCAM KRAS KRT7 MEN1
2 digestive/alimentary MP:0005381 10.22 CDX2 CTNNB1 EPCAM GAST HRAS KRAS
3 homeostasis/metabolism MP:0005376 10.22 CDX2 CTNNB1 EPCAM GAST HRAS KRAS
4 endocrine/exocrine gland MP:0005379 10.15 AFAP1 CDX2 CTNNB1 EPCAM GAST HRAS
5 immune system MP:0005387 10.03 CTNNB1 EPCAM GAST KRAS MEN1 MLH1
6 integument MP:0010771 9.81 AFAP1 CTNNB1 HRAS KRAS MLH1 MSH2
7 mortality/aging MP:0010768 9.8 CDX2 CTNNB1 EPCAM GAST HRAS KRAS
8 neoplasm MP:0002006 9.44 CDX2 CTNNB1 GAST HRAS KRAS MEN1

Drugs & Therapeutics for Small Intestine Cancer

Drugs for Small Intestine Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prucalopride Approved Phase 4 179474-81-8
2 Gastrointestinal Agents Phase 4
3 Neurotransmitter Agents Phase 4
4 Serotonin Agents Phase 4
5 Cathartics Phase 4
6 Laxatives Phase 4
7 Serotonin Receptor Agonists Phase 4
8
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
9
Ondansetron Approved Phase 3 99614-02-5 4595
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Cola Phase 3
13 Liver Extracts Phase 3
14 Antineoplastic Agents, Hormonal Phase 3
15 Antiemetics Phase 3
16 Autonomic Agents Phase 3
17 Serotonin Antagonists Phase 3
18 Central Nervous System Depressants Phase 3
19
protease inhibitors Phase 3
20 Anti-Anxiety Agents Phase 3
21 Antipruritics Phase 3
22 Antipsychotic Agents Phase 3
23 Tranquilizing Agents Phase 3
24 Dermatologic Agents Phase 3
25 Hormone Antagonists Phase 3
26 HIV Protease Inhibitors Phase 3
27 Psychotropic Drugs Phase 3
28 glucocorticoids Phase 3
29 Narcotics Phase 3
30 Anesthetics Phase 3
31 Anesthetics, General Phase 3
32 Analgesics, Opioid Phase 3
33 Adjuvants, Anesthesia Phase 3
34 Anesthetics, Intravenous Phase 3
35
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
36
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
37
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
38
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
39
Floxuridine Approved Phase 2 50-91-9 5790
40
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
41
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
42
Lenograstim Approved, Investigational Phase 2 135968-09-1
43
Gemcitabine Approved Phase 2 95058-81-4 60750
44
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
45
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
46
Hydroxyurea Approved Phase 2 127-07-1 3657
47
Fluorouracil Approved Phase 2 51-21-8 3385
48
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
49
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
50
Melphalan Approved Phase 2 148-82-3 4053 460612

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
3 Does Bowel Preparation (Either as a Single or Divided Dose) Produce Better Cleansing and Diagnostic Yield Than no Preparation at All in Small Bowel Capsule Endoscopy Recruiting NCT03351972 Phase 4 Klean Prep
4 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
5 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 Chemoprevention of Duodenal Polyps in Familial Adenomatous Polyposis Withdrawn NCT00026468 Phase 2, Phase 3 exisulind
7 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
8 A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase Completed NCT00248404 Phase 1, Phase 2 NB1011
9 Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
10 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
11 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
12 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
13 A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
14 Phase II Study of Abraxane in CIMP-High Colorectal Adenocarcinomas and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
15 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
16 Phase II Study of Panitumumab in KRAS Wild-type Locally Advanced or Metastatic Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed NCT01202409 Phase 2 Panitumumab
17 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
18 A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
19 A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater Completed NCT00354887 Phase 2 Capecitabine;Oxaliplatin
20 Pilot Study to Investigate the Safety and Efficacy of Avelumab Monotherapy in Patients With Advanced or Metastatic Adenocarcinoma of the Small Intestine Active, not recruiting NCT03000179 Phase 2 Avelumab
21 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
22 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Small Intestine Terminated NCT00003522 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
23 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
24 A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting Terminated NCT00903396 Phase 2 palonosetron hydrochloride
25 Study of "Same TCM Syndrome for Different Diseases" and "Same Treatment for Different Diseases" of Primary Hepatocellular Carcinoma and Colorectal Cancer Under the Perspective of System Science Unknown status NCT03189992 Phase 1 Bushen-Jianpi Dedoction;cinobufotalin injection
26 A Phase I Clinical Trial of Intrapleural Adenoviral-Mediated Interferon-beta (IFN-ß) Gene Transfer for Pleural Malignancies Unknown status NCT00066404 Phase 1
27 Pilot Study of Oxaliplatin in Combination With Capecitabine in Adult Cancer Patients Completed NCT00019773 Phase 1 capecitabine;oxaliplatin
28 Phase I Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis, Associated With Mullerian and Gastrointestinal Carcinomas Completed NCT00003046 Phase 1
29 A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
30 Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies Completed NCT00003867 Phase 1 capecitabine;irinotecan hydrochloride
31 Phase I Study of Intraperitoneal Administration of 9-Amino-20(S)-Camptothecin to Patients With Cancer Predominantly Confined to the Peritoneal Cavity Completed NCT00003548 Phase 1 aminocamptothecin colloidal dispersion
32 A Phase I Dose-Escalating Study of Recombinant Human Interleukin-12 (NSC # 672423) Administered by Intraperitoneal Infusion in Refractory Advanced Stage Ovarian Cancer and Other Abdominal Carcinomatosis Completed NCT00003439 Phase 1
33 Phase I Study to Evaluate the Combination Chemotherapy Regimen of Oxaliplatin Plus Irinotecan in Previously Treated Patients With Metastatic Gastrointestinal Cancer Completed NCT00003427 Phase 1 irinotecan hydrochloride;oxaliplatin
34 A Phase I Clinical Trial To Assess The Safety And Efficacy Of Intraperitoneal PV701 Administrations In Patients With Advanced Or Recurrent Malignancy Largely Confined To The Peritoneal Cavity Completed NCT00055705 Phase 1
35 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
36 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
37 PHASE I PILOT STUDY OF SEQUENTIAL HIGH DOSE CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE AND IFOSFAMIDE, CARBOPLATIN AND TAXOL WITH AUTOLOGOUS STEM CELL SUPPORT Completed NCT00002854 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;ifosfamide;mesna;paclitaxel
38 A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
39 A Phase I Study of Oral Fluoropyrimidine Capecitabine (Xeloda Roche) Combined With Intravenous Cisplatin in Patients With Advanced Cancer of the Digestive System Completed NCT00010023 Phase 1 capecitabine;cisplatin
40 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
41 Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles Completed NCT00049296 Phase 1 docetaxel;thalidomide
42 A Capsule Endoscopy and Double Balloon Enteroscopy Sequential Approach for Early Detection of Gastrointestinal Tumors in Celiac Disease: a Prospective Trial Unknown status NCT02325232
43 Open Prospective Single Center Study for the Determination of Correlation Between Video Capsule Period of Retention in the Stomach and Symptoms of Gastroparesis Unknown status NCT01858220
44 Endoscopic Evaluation of the Incidence and Etiology of Lower Gastrointestinal Bleeding in Patients Presenting With Melena Completed NCT00164723
45 Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors Completed NCT02150148
46 Capsule Endoscopy in Lynch Syndrome for Small Intestinal Tumor Screening Completed NCT00898768 Early Phase 1
47 Assessing the Clinical Significance of Real-time Quality of Life Data in Cancer Patients Treated With Radiation Therapy Completed NCT00836992
48 Improving Palliative Care for Patients With Cancer Completed NCT00253383
49 Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers Recruiting NCT03978078
50 A Prospective Comparison of Diagnostic Efficacy and Radiomics Study in the Diagnosis and Therapeutic Efficacy Evaluation of Small Bowel Tumor With Dual-phase Enhanced Computed Tomography (CTE) and Magnetic Resonance Enterography (MRE) Enrolling by invitation NCT03659357

Search NIH Clinical Center for Small Intestine Cancer

Genetic Tests for Small Intestine Cancer

Anatomical Context for Small Intestine Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Small Intestine Cancer:

19
Small Intestine

MalaCards organs/tissues related to Small Intestine Cancer:

40
Small Intestine, Colon, Thyroid, Lung, Liver, Breast, Skin

Publications for Small Intestine Cancer

Articles related to Small Intestine Cancer:

(show top 50) (show all 57)
# Title Authors PMID Year
1
High prevalence of Pentatrichomonas hominis infection in gastrointestinal cancer patients. 61
31462294 2019
2
Epidemiology of Cancers of the Small Intestine: Trends, Risk Factors, and Prevention. 61
30884915 2019
3
Diabetes in midlife and risk of cancer in late life: A nationwide Swedish twin study. 61
29566433 2018
4
Adiposity and risks of colorectal and small intestine cancer in Chinese adults: a prospective study of 0.5 million people. 61
29872150 2018
5
Body mass index and gastrointestinal cancer mortality in Korean adults: A prospective cohort study. 61
29406580 2018
6
[Asystole during surgery to manage small intestine cancer: are we dealing with anaphylaxis or carcinoid crisis]. 61
30344876 2018
7
Incidentally Detected Small Intestine Intussusception Caused by Primary Small Intestine Carcinoma on 18F-FDG PET/CT. 61
28878855 2017
8
Locoregional Effects of Microbiota in a Preclinical Model of Colon Carcinogenesis. 61
28416491 2017
9
A systematic review of the possible carcinogenic role of the aristolochic acid. 61
28523296 2017
10
[A Case of a Single Incisional Laparoscopic Assisted Partial Jejunectomy Performed to Treat a Primary Small Intestine Cancer in a Young Woman]. 61
28133098 2016
11
Temporal Trends, Predictors, and Outcomes of In-Hospital Gastrointestinal Bleeding Associated With Percutaneous Coronary Intervention. 61
27642112 2016
12
Cost of specific emergency general surgery diseases and factors associated with high-cost patients. 61
26502214 2016
13
Chemoprevention trials of GI cancers in Asia. 61
26651257 2015
14
[A Case of Small Intestinal Cancer Repeating an Ileus Symptom Complicated with Refractory Arrhythmia]. 61
26805146 2015
15
Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5. 61
26421818 2015
16
Empirical Likelihood for Censored Linear Regression and Variable Selection. 61
31097849 2015
17
Focus on the diagnostic problems of primary adenocarcinoma of the third and fourth portion of the duodenum. Case report. 61
26712074 2015
18
[A case of an elderly patient who underwent single-incision laparoscopic surgery for small intestine cancer]. 61
25731551 2014
19
Is additional enrichment of diet in branched-chain amino acids or glutamine beneficial for patients receiving total parenteral nutrition after gastrointestinal cancer surgery? 61
24979515 2014
20
Increased incidence of gastrointestinal cancers among patients with pyogenic liver abscess: a population-based cohort study. 61
24095786 2014
21
An unusual cause of the ileus: non-specific stenosing ulceration of the small intestine. 61
23390850 2012
22
Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. 61
22169462 2012
23
Body mass, tobacco smoking, alcohol drinking and risk of cancer of the small intestine--a pooled analysis of over 500,000 subjects in the Asia Cohort Consortium. 61
22147734 2012
24
Antioxidants in patients receiving total parenteral nutrition after gastrointestinal cancer surgery. 61
22125185 2012
25
Role of solar UVB irradiance and smoking in cancer as inferred from cancer incidence rates by occupation in Nordic countries. 61
22928078 2012
26
Sugars in diet and risk of cancer in the NIH-AARP Diet and Health Study. 61
21328345 2012
27
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. 61
22180306 2012
28
[A case report of multiple adenocarcinoma in small intestine after total gastrectomy by Roux-en-Y re-construction]. 61
22202278 2011
29
Epidemiology of cancer of the small intestine. 61
21461167 2011
30
[Two cases of the primary small intestine cancer successfully treated with S-1 and UFT/LV therapy]. 61
21224714 2010
31
SEMIPARAMETRIC ADDITIVE RISKS REGRESSION FOR TWO-STAGE DESIGN SURVIVAL STUDIES. 61
21931467 2010
32
Small intestinal adenocarcinoma in common marmosets (Callithrix jacchus). 61
20460447 2010
33
Small intestinal cancer: a population-based study of incidence and survival patterns in the United States, 1992 to 2006. 61
20647399 2010
34
Patient with eight metachronous gastrointestinal cancers thought to be hereditary nonpolyposis colorectal cancer (HNPCC). 61
20118596 2010
35
Hemorrhagic small intestine cancer with solitary pulmonary metastasis initially presented as suspected primary lung cancer: an autopsy report. 61
18432067 2007
36
Socioeconomic and geographic determinants of survival of patients with digestive cancer in France. 61
16969351 2006
37
Associations between small intestine cancer and other primary cancers: an international population-based study. 61
16003748 2006
38
[Case with double primary cancers occurring synchronously in both the lung and jejunum diagnosed according to TTF-1 expression]. 61
15770938 2005
39
Accumulation of the oxidative base lesion 8-hydroxyguanine in DNA of tumor-prone mice defective in both the Myh and Ogg1 DNA glycosylases. 61
15231648 2004
40
Up-regulation in dihydropyrimidine dehydrogenase activity by raltitrexed causes antagonism in combination with 5-fluorouracil. 61
14981911 2003
41
Leiomyosarcoma of the small intestine found within an inguinal hernia sac: a case report. 61
12914376 2003
42
Cancer incidence among Swedish patients exposed to radioactive thorotrast: a forty-year follow-up survey. 61
11893244 2002
43
Iron deficiency anemia as the sole symptom of small intestine carcinoma. 61
11386025 2001
44
[Metastatic small intestine carcinoma--delayed diagnosis due to misinterpretation of diagnostic imaging and symptom confusion due to Bechterew disease and duodenal ulcer]. 61
10923361 2000
45
Cyclic core dendrimer as a new kind of vector for gene transfer into mammalian cells. 61
11145421 2000
46
Suspected hereditary nonpolyposis colorectal cancer: International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) criteria and results of genetic diagnosis. 61
10378593 1999
47
Effect of tea extracts, polyphenols, and epigallocatechin gallate on azoxymethane-induced colon cancer. 61
9421213 1998
48
[Duodenal adenocarcinoma in celiac disease with late diagnosis and treatment]. 61
9280612 1997
49
[Study of p53 protein expression in cancers of small intestine and its relationship to clinical course and prognosis]. 61
9387321 1996
50
Risk factors for small intestine cancer. 61
8481495 1993

Variations for Small Intestine Cancer

Expression for Small Intestine Cancer

Search GEO for disease gene expression data for Small Intestine Cancer.

Pathways for Small Intestine Cancer

Pathways related to Small Intestine Cancer according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.86 TP53 MSH6 MSH2 MLH1 KRAS HRAS
2
Show member pathways
12.64 TP53 SMAD4 MLH1 KRAS HRAS CTNNB1
3
Show member pathways
12.61 TP53 SMAD4 MSH6 MSH2 MLH1 KRAS
4
Show member pathways
12.52 TP53 MSH2 KRAS HRAS CTNNB1
5 12.48 TP53 SMAD4 MSH6 MSH2 MLH1 KRAS
6 12.43 TP53 MUTYH MSH6 MSH2 MLH1
7
Show member pathways
12.39 TP53 MUC1 KRAS HRAS CTNNB1
8
Show member pathways
12.32 MUC6 MUC5AC MUC1 KRAS HRAS
9 12.28 TP53 SMAD4 KRAS HRAS
10 12.24 TP53 KRAS HRAS CTNNB1
11
Show member pathways
12.16 KRAS HRAS EPCAM CEACAM5
12 12.02 SMAD4 KRAS HRAS CTNNB1
13 11.99 TP53 PMS2 MSH2 MLH1
14 11.94 MUC1 EPCAM CTNNB1 CEACAM5
15 11.91 TP53 KRAS HRAS CTNNB1
16 11.87 TP53 KRAS HRAS CTNNB1
17 11.86 TP53 SMAD4 KRAS HRAS CTNNB1
18
Show member pathways
11.76 PMS2 MSH6 MSH2 MLH1
19
Show member pathways
11.75 TP53 MSH6 MSH2
20 11.69 TP53 KRAS HRAS
21 11.65 TP53 KRAS HRAS
22 11.62 TP53 KRAS HRAS
23 11.62 TP53 MSH6 MSH2 MLH1
24 11.62 TP53 SMAD4 MSH6 MSH2 KRAS CTNNB1
25 11.56 SMAD4 HRAS CTNNB1
26 11.44 TP53 MSH6 MSH2
27 11.38 TP53 SMAD4 MSH6 MSH2 MLH1 KRAS
28
Show member pathways
11.36 TP53 MSH2 MLH1
29 11.15 SMAD4 KRAS HRAS CTNNB1
30 11.09 PMS2 MSH6 MSH2 MLH1
31 10.47 MUC6 GAST

GO Terms for Small Intestine Cancer

Cellular components related to Small Intestine Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10 TP53 SMAD4 PMS2 MUTYH MSH6 MSH2
2 MutLalpha complex GO:0032389 9.16 PMS2 MLH1
3 MutSalpha complex GO:0032301 8.96 MSH6 MSH2
4 mismatch repair complex GO:0032300 8.92 PMS2 MSH6 MSH2 MLH1

Biological processes related to Small Intestine Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.98 TP53 SMAD4 MEN1 HRAS CTNNB1
2 in utero embryonic development GO:0001701 9.9 TP53 SMAD4 MSH2 CTNNB1
3 DNA repair GO:0006281 9.88 PMS2 MUTYH MSH6 MSH2 MLH1 MEN1
4 cellular response to DNA damage stimulus GO:0006974 9.87 TP53 PMS2 MUTYH MSH6 MSH2 MLH1
5 Ras protein signal transduction GO:0007265 9.77 TP53 KRAS HRAS
6 O-glycan processing GO:0016266 9.75 MUC6 MUC5AC MUC1
7 response to UV GO:0009411 9.71 TP53 MSH6 MEN1
8 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.7 MSH6 MSH2 MLH1
9 intrinsic apoptotic signaling pathway GO:0097193 9.65 TP53 MSH6 HRAS
10 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.65 MUC6 MUC5AC MUC1 KRAS HRAS
11 response to transforming growth factor beta GO:0071559 9.62 SMAD4 MEN1
12 negative regulation of telomerase activity GO:0051974 9.62 TP53 MEN1
13 response to UV-B GO:0010224 9.61 TP53 MSH2
14 positive regulation of isotype switching to IgG isotypes GO:0048304 9.61 MSH2 MLH1
15 determination of adult lifespan GO:0008340 9.61 TP53 MSH6 MSH2
16 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.57 TP53 MUC1
17 response to isolation stress GO:0035900 9.56 KRAS HRAS
18 positive regulation of helicase activity GO:0051096 9.55 MSH6 MSH2
19 isotype switching GO:0045190 9.54 MSH6 MSH2 MLH1
20 positive regulation of isotype switching to IgA isotypes GO:0048298 9.51 MSH2 MLH1
21 maintenance of DNA repeat elements GO:0043570 9.49 MSH6 MSH2
22 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.46 MSH2 MLH1
23 somatic recombination of immunoglobulin gene segments GO:0016447 9.33 MSH6 MSH2 MLH1
24 somatic hypermutation of immunoglobulin genes GO:0016446 9.26 PMS2 MSH6 MSH2 MLH1
25 mismatch repair GO:0006298 9.02 PMS2 MUTYH MSH6 MSH2 MLH1

Molecular functions related to Small Intestine Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.91 TP53 SMAD4 MSH6 MSH2 MLH1 MEN1
2 enzyme binding GO:0019899 9.89 TP53 MSH6 MSH2 MLH1 CTNNB1
3 ATPase activity GO:0016887 9.85 PMS2 MSH6 MSH2 MLH1
4 protein C-terminus binding GO:0008022 9.81 TP53 MSH2 HRAS CTNNB1
5 double-stranded DNA binding GO:0003690 9.78 MSH6 MSH2 MEN1 CDX2
6 RNA polymerase II transcription factor binding GO:0001085 9.7 TP53 SMAD4 CTNNB1
7 four-way junction DNA binding GO:0000400 9.58 MSH6 MSH2 MEN1
8 I-SMAD binding GO:0070411 9.54 SMAD4 CTNNB1
9 MutSalpha complex binding GO:0032407 9.5 PMS2 MUTYH MLH1
10 single guanine insertion binding GO:0032142 9.46 MSH6 MSH2
11 single thymine insertion binding GO:0032143 9.43 MSH6 MSH2
12 MutLalpha complex binding GO:0032405 9.43 MUTYH MSH6 MSH2
13 oxidized purine DNA binding GO:0032357 9.33 MUTYH MSH6 MSH2
14 guanine/thymine mispair binding GO:0032137 9.13 MSH6 MSH2 MLH1
15 mismatched DNA binding GO:0030983 8.92 PMS2 MSH6 MSH2 MLH1

Sources for Small Intestine Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....